ProMIS’s PMN310 Antibody Therapy Binds Only to Toxic Forms of Amyloid Beta, Study Reports

ProMIS’s PMN310 Antibody Therapy Binds Only to Toxic Forms of Amyloid Beta, Study Reports
An antibody therapy that ProMIS Neurosciences is developing for Alzheimer’s formed a bond with only the harmful forms of amyloid beta clusters associated with the disease, an indication that it could be an effective treatment, according to a preclinical-trial study. A good sign was that PMN310 didn’t bind to the forms that are non-toxic, ProMIS said. The

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *